ArticleMDM policy & practice
The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers.
Article in MDM policy & practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review.PharmacoEconomics · 2025Pooled it
- Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.JAMA network open · 2022Pooled it
- Pooled it
- Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada.Current oncology (Toronto, Ont.) · 2026Article
- Article
- CodeBreaK or code blue? Assessing sotorasib's vital signs in metastatic colorectal cancer.Cancer · 2025Article
- Assessment of Patient and Clinician Perspectives on Clinically Meaningful Extension of Progression-free Survival in Prostate Cancer.European urology open science · 2024Article
- Article
- The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer.The patient · 2022Article
- Brazilian breast cancer patient-reported outcomes: What really matters for these women.Frontiers in medical technology · 2022Article
- Article
- Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast Cancer.Current oncology (Toronto, Ont.) · 2021Article
- Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.